Results 211 to 220 of about 2,958,013 (281)

Platelet-Rich Plasma: Are We Ahead of the Evidence? [PDF]

Arch Bone Jt Surg
Shahrezaee M, Noroozi-Aghideh A.
europepmc   +1 more source

AI‐Driven Rational Design of Nanotherapeutics for Pancreatic Ductal Adenocarcinoma

Medicinal Research Reviews, EarlyView.
ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) remains a formidable malignancy characterized by late diagnosis, high recurrence rates, and pronounced chemoresistance. While nanoparticle‐based drug delivery systems (NDDS) offer theoretical advantages over conventional therapies, their clinical translation in PDAC has been severely limited.
Seohyun Choo, Kaeun Chae, Jueun Lee, Inseon Kim, Seunghun S. Lee   +4 more
wiley   +1 more source

Immune heterogeneity-driven therapeutic responses to platelet-rich plasma and TRPV1 antagonism in osteoarthritis. [PDF]

Front Pharmacol
Liu P, Zhu J, Yang Y, Kou H, Yin F, Yang L.   +5 more
europepmc   +1 more source

Aptamer–Based Targeted Protein Degradation: Mechanistic Principles, Delivery Strategies, and Translational Opportunities

Medicinal Research Reviews, EarlyView.
ABSTRACT Targeted elimination of pathogenic proteins remains a fundamental challenge in therapeutic intervention, particularly for proteins considered “undruggable” by conventional inhibition‐based approaches. Aptamer–based targeted protein degradation (TPD) has emerged as a versatile strategy that leverages the high specificity, structural ...
Ambrin Malik, Suyeon Son, Jaesung Lee, Ki Soo Park   +3 more
wiley   +1 more source

The clinical applications of platelet-rich plasma and platelet-rich fibrin combined with photobiomodulation in regenerative dentistry: A literature review. [PDF]

J Dent Sci
Pourhajibagher M, Bahrami R, Bahador A.
europepmc   +1 more source

Current status and future perspectives of platelet function‐guided precision antiplatelet therapy for patients with cerebral infarction

Neuroprotection, EarlyView.
Antiplatelet agents target the cyclooxygenase‐1 (COX‐1)/thromboxane A2 (TXA2) and adenosine diphosphate (ADP)‐P2Y12 (cytochrome P450 2C19 [CYP2C19]‐metabolized) platelet activation pathways, resulting in either drug resistance or over‐inhibition. The individualized therapeutic window balances ischemic risk (triggered by high on‐treatment platelet ...
Guoliang Zhu, Xiaoling Chen, Xinyi Huang, Quandan Tan, Qing Cao, Yali Yang, Yapeng Lin, Jie Yang   +7 more
wiley   +1 more source

Age-Specific Efficacy of Platelet-Rich Plasma in Tonsillectomy: A Systematic Review and Meta-Analysis. [PDF]

J Clin Med
Kim JS, Stybayeva G, Hwang SH.
europepmc   +1 more source

Risk of septic arthritis following corticosteroid and platelet‐rich plasma injections: A multicenter retrospective review

PM&R, EarlyView.
Abstract Background Platelet‐rich plasma injections (PRPI) are a relatively new and evolving treatment option for a variety of musculoskeletal injuries. It has been theorized that there is an increased risk of septic arthritis (SA) with PRPI, though there have been no dedicated studies to assess the incidence of SA and only three cases have been ...
Kory Ford, James Frazier, Anthony Beutler, Catherine Fairgrieve Appel, Daniel M. Cushman   +4 more
wiley   +1 more source

Research Progress on Platelet-Rich Plasma (PRP) in the Treatment of Androgenetic Alopecia. [PDF]

J Cosmet Dermatol
Zhong Z, Luo L, Zhao L, Yue X, Lu Y.
europepmc   +1 more source